Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Gilbert

Otolaryngology/Facial Plastic Surgery Elkhart, IN Doctor of Osteopathy

NPI 1275735581 CMS profile 57383

1753 Fulton St, Elkhart, IN 46514

Open in the dashboard

General payments

$24,353

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$50,960 paid to institutions, not to them · program years 2020–2021

Through program year 2025, John Gilbert of Elkhart, IN is reported in the CMS Open Payments database as having received $24,353 across 166 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $50,960 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Otolaryngology/Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,865 44
2024 General $1,914 34
2023 General $868 17
2022 General $1,161 17
2021 General $509 10
2020 General $1,100 20
2019 General $1,938 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Gilbert
  • Otolaryngology/Facial Plastic Surgery median
  • Middle half of Otolaryngology/Facial Plastic Surgery
  • National median

In program year 2025, general payments to John Gilbert were reported at $16,865. Among 526 Otolaryngology/Facial Plastic Surgery profiles paid that year, the median was $306 and the middle half received between $100 and $757.

Show as a table
Year John Gilbert Otolaryngology/Facial Plastic Surgery median Middle half National median
2019 $1,938 $237 $98–$548 $163
2020 $1,100 $118 $46–$265 $114
2021 $509 $179 $69–$469 $132
2022 $1,161 $212 $94–$520 $149
2023 $868 $225 $97–$552 $160
2024 $1,914 $285 $111–$707 $164
2025 $16,865 $306 $100–$757 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spirair, Inc. $15,284 3 payments
  2. Aerin Medical Inc. $3,835 36 payments
  3. Stryker Corporation $1,585 22 payments
  4. Acclarent, Inc $899 16 payments
  5. Integra LifeSciences Corporation $419 4 payments
  6. Smith+Nephew, Inc. $374 11 payments
  7. Inspire Medical Systems, Inc. $362 17 payments
  8. Neurent Medical Limited $360 5 payments
  9. Medtronic, Inc. $350 10 payments
  10. Intersect ENT, Inc. $214 8 payments
  11. Other $672 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,200 1 payment
  2. Food and Beverage $8,979 161 payments
  3. Honoraria $800 1 payment
  4. Travel and Lodging $340 2 payments
  5. Education $34 1 payment
Products named General payments · program years 2019–2025
  1. SeptAlign Otolarynology $15,284 3 payments
  2. SeptAlign Otolarynology $15,284 3 payments
  3. TURBALIGN Otolarynology $15,003 2 payments
  4. TURBALIGN Otolarynology $15,003 2 payments
  5. RHINAER STYLUS $1,538 18 payments
  6. VIVAER STYLUS $1,538 18 payments
  7. Vivaer RF Stylus $1,203 7 payments
  8. ENTELLUS - XPRESS ENT DILATION SYSTEM $584 12 payments
  9. TruDi NAV Cable $441 6 payments
  10. INSPIRA AIR $406 3 payments
  11. Other $5,434 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

720

Median for Otolaryngology: 297

Drug cost

$72,351

Median for Otolaryngology: $6,314

Branded share of claims

23.1%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 15 $59,967
Ipratropium Bromide Generic 203 $5,000
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 11 $1,293
Azelastine Hcl Generic 39 $1,249
Cefuroxime Cefuroxime Axetil Brand 53 $1,070
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 13 $755
Doxycycline Hyclate Generic 29 $444
Ofloxacin Generic 20 $424
Mupirocin Generic 63 $386
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 36 $354

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$114,295

Medicare's payments for the services billed

Medicare patients

323

Average age 73

Services billed

1,219

194 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 42%
Ischemic heart disease 29%
Diabetes 25%
Depression 20%
Osteoporosis 20%
Atrial fibrillation 17%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $76
  • Regeneron Healthcare Solutions, Inc. $17
$93 15 —
SINUVA
  • Medtronic, Inc. $29
$29 — —
NUCALA
  • GlaxoSmithKline, LLC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology/Facial Plastic Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record